Simulated Moving Bed Chromatography: A Powerful Unit Operation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Simulated Moving Bed Chromatography: A Powerful Unit Operation
High performance liquid chromatography has become an efficient technique at the production scale, and simulated moving bed chromatography provides several benefits during processing.


Pharmaceutical Technology



Figure 2: Example of a loading study. By increasing the volume injected, the peaks change shape according to their equilibrium isotherm. This information is used to model the SMB process and calculate the throughput. (FIGURE: AMPAC FINE CHEMICALS)
Determine the amount that can be separated. The "loading study" step is aimed at determining the maximum loading capacity of the CSP. The study consists of injecting on an analytical column (4.6-mm diameter X 250-mm long) packed with preparative CSP (typically 16 or 20 μm) an increasing volume of a concentrated solution of the racemic mixture until the separation is lost (see Figure 2). From these data valuable information about the behavior of the compound as a function of the concentration is collected. This information is entered into a computer model which in turn calculates the parameters required to operate an SMB unit. At this point an estimation of the production rate is obtained and the size of the SMB unit required to produce the desired amount of the single enantiomer can be calculated.


Figure 3: Bench-top simulated moving bed unit, 8 columns of 4.6 mm or 1 cm in diameter. This unit is used for proof of concept. (PHOTO: AMPAC FINE CHEMICALS)
Demonstrate proof of concept. Simulations are not always perfect, and it is usually a good practice to demonstrate the separation on a small-scale unit. On such a unit, equipped with columns of 4.6 or 10 mm in diameter, 20–200 g of material can be processed (see Figure 3). This amount is enough to achieve steady state and obtain a representative sample of the product. The columns can be packed in house or purchased from the packing manufacturer.

This step can take 2–4 weeks, which is long enough to evaluate the productivity as well as the robustness and the stability of the separation. At this stage, chemists can start developing the isolation process post-SMB separation (e.g, crystallization, solvent exchange, drying).

Scale-up for clinical quantities. The scale-up from the demonstration run is straightforward. Chromatography processes are scaled up on the basis of the linear velocity at the particle level (i.e., the flow rate is multiplied by the ratio of the column diameters squared.) For example, if 50 g of racemic feed can be processed per day on a 10-mm diameter column, then a 50-mm SMB unit can process 1250 g per day (25X). This is a very easy process to scale-up. As a matter of fact, performances often improve with the diameter of the columns because of the favorable ratio of column to piping volume.

Following the demonstration step, it is frequent that 5–25 kg are separated using the 8 X 50-mm unit to supply material for Phase I. This material can be made according to current good manufacturing practices and purified in a matter of weeks. This work is still conducted on lab-scale equipment, and the overall cost is very reasonable.

Conduct production at pilot scale. Typically, a campaign involving the separation of 200–500 kg of racemic feed follows the scale-up phase. Normally, this is to supply material for Phase II or Phase III clinical trials. At this stage, the separation process is well characterized. The effort is more concentrated in the handling of solvent (recycling, composition adjustment etc.) and the product recovery (solvent exchange, crystallization, drying, etc.). All these steps are conducted in equipment that is similar to commercial-scale units. This provides a complete and accurate picture of the final process at commercial scale.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
11%
To select process for new products only
25%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here